** New Zealand listed shares of Pacific Edge PEB.NZ rise as much as 17.7% to A$0.166, their highest level since October 8, 2024
** Cancer diagnostics firm says US Centers for Medicare & Medicaid Services $(CMS)$ have recommended a higher final price for co's urothelial cancer diagnostics product - Cxbladder Triage Plus1 -than their proposed price in April
** CMS sets the amount co will receive in reimbursements for all patients with Medicare and Medicare Advantage insurance for the product
** New recommended price is US$1,328.32, up from the US$1,018 proposed in April, co says
** Stock posts its biggest intraday pct gain since April 29
** Around 2.5 mln shares change hands, 4.8x the 30-day average trading volume
** Last up 9.9%, bringing YTD gains to 24%
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))